A longitudinal study of an unusual rapidly progressive dementia case: A Case report
![](https://sciaxis.org/wp-content/uploads/2023/05/analyzing-results-field-interview.jpg)
![](https://sciaxis.org/wp-content/uploads/2023/05/analyzing-results-field-interview.jpg)
A 74-year-old, right-handed male was admitted with complaints of jaw and bilateral hand movements for 3 months and
Functional Movement Disorder and Parkinson’s Disease Comorbidity: A Case Report
![](https://sciaxis.org/wp-content/uploads/2022/11/tired-businessman-serious-young-man-yellow-studio-with-headache-emotions-1024x683.jpg)
![](https://sciaxis.org/wp-content/uploads/2022/11/tired-businessman-serious-young-man-yellow-studio-with-headache-emotions-1024x683.jpg)
Case Presentation A 22-year-old male patient presented to the emergency room of hospital with chief complaints of restlessness, an intolerable urge to pace around, suspiciousness, and sleep disturbances in the form of late-onset and midnight awakenings for four days. Medical History Family History Clinical Exam Treatment Clinical Outcome Careful observation, interviews, and periodic mental status […]
FDA Approves Another Drug for Schizophrenia and Bipolar I Disorder
![FDA Approves Another Drug for Schizophrenia and Bipolar I Disorder](https://sciaxis.org/wp-content/uploads/2021/07/FDA-Approves-Another-Drug-for-Schizophrenia-and-Bipolar-e1626021853729-1024x684.jpg)
![FDA Approves Another Drug for Schizophrenia and Bipolar I Disorder](https://sciaxis.org/wp-content/uploads/2021/07/FDA-Approves-Another-Drug-for-Schizophrenia-and-Bipolar-e1626021853729-1024x684.jpg)
For the management of schizophrenia and bipolar I disorder, US FDA recently approved a once-daily oral combination medication of olanzapine and samidorphan. Olanzapine on its own is highly efficacious but demonstrates side effects such as weight gain. In the ENLIGHTEN-2 study, the combination has proven its efficacy along with significantly less weight gain than olanzapine […]